论文部分内容阅读
由于大多数胰腺癌患者被确诊时已无法施行手术治疗,只有10％～20％的病人有手术切除的机会,因此早期准确诊断是提高病人预后的关键。本文报导一种新的胰腺癌标志物CA494及其临床价值。 CA494抗原是单克隆抗体BW494确定的,该抗体对胰腺胆管癌(Ⅰ,Ⅱ级)有高度免疫组化结合力;并可通过人类肠癌细胞株免疫BALB/C鼠获得。单克隆抗体BW494能识别定位在分子量大于200kD糖蛋白的一个碳水化合物样抗原决定簇。但CA494抗原的确切结构
Since most patients with pancreatic cancer are unable to undergo surgical treatment when they are diagnosed, only 10% to 20% of patients have the opportunity to undergo surgical resection. Therefore, early and accurate diagnosis is the key to improving patient prognosis. This article reports a novel pancreatic cancer marker CA494 and its clinical value. The CA494 antigen is defined by the monoclonal antibody BW494, which has high immunohistochemical binding to pancreatic cholangiocarcinoma (grades I and II) and can be obtained by immunizing BALB/C mice with human colon cancer cell lines. The monoclonal antibody BW494 can recognize a carbohydrate-like epitope that is located in a glycoprotein with a molecular weight greater than 200 kD. But the exact structure of the CA494 antigen